[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxcarbazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oxcarbazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oxcarbazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aucta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aucta Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Trileptin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Study Phase : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat parti...

                          Product Name : Trileptal-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Aucta Company Banner

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Oxtellar XR-Generic (oxcarbazepine) is an antiepileptic drug (AED) indicated for the treatment of partial-onset seizures in patients aged six years and older.

                          Product Name : Oxtellar XR-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 09, 2025

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Oxcarbazepine tablets produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to tre...

                          Product Name : Trileptal-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 04, 2023

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Collaborative Care Initiative, LLC

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Collaborative Care Initiative, LLC

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Details : Oxcarbazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bipolar Disorder.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 26, 2018

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Massachusetts General Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Queen Mary University of London

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Queen Mary University of London

                          Country arrow
                          Luxepack
                          Not Confirmed

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Study Phase : Phase II

                          Sponsor : National Multiple Sclerosis Society | Novartis Pharmaceuticals Corporation | Barts & The London NHS Trust | University College, London | Royal Free Hospital NHS FT | Mid and South Essex NHS FT | St George's Healthcare NHS Trust | Barnet and Chase Farm Hos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Oxcarbazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 04, 2014

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : National Multiple Sclerosis Society | Novartis Pharmaceuticals Corporation | Barts & The London NHS Trust | University College, London | Royal Free Hospital NHS FT | Mid and South Essex NHS FT | St George's Healthcare NHS Trust | Barnet and Chase Farm Hos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Oxcarbazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Seizures.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 10, 2012

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Oxcarbazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Seizures.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 08, 2012

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Oxcarbazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Epilepsies, Partial.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 18, 2010

                          Lead Product(s) : Oxcarbazepine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank